Risk Factors
While RSV-related infections usually present as mild cold-like symptoms in adults, some cases may lead to more serious respiratory complications, hospitalization and death, particularly in older adults and those with underlying conditions1
A large prospective study estimated the incidence of RSV-associated hospitalization in two regions of New York State, USA, 2017–2020. N=1099 cases:4
This graph was independently created for GSK from the original data
Comorbidity | Incidence rate ratio* | |
---|---|---|
Rochester |
NYC | |
COPD | ||
50-64y |
6.35 |
6.30 |
≥65y |
13.41 |
3.51 |
Asthma |
||
50-64y | 2.34 | 3.60 |
≥65y | 2.52 | 2.27 |
Diabetes | ||
50-64y | 3.36 | 3.58 |
≥65y | 6.44 | 2.35 |
CAD | ||
50-64y | 3.74 | 4.41 |
≥65y | 6.46 | 3.75 |
CHF | ||
60-79y | 7.63 | 5.86 |
≥80y | 3.99 | 5.40 |
*Ratio of rate among people with each comorbidity versus those without it, in the surveillance area population
In older adults hospitalized with RSV, the risk of severe outcomes is comparable to those hospitalized with influenza
This graph was independently created for GSK from the original data
CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; NYC, New York City; RSV, respiratory syncytial virus
Material supplied by the above-country business unit to LOCs for localisation must be subject to local Medical and/or Regulatory review and approval prior to use and/or external distribution.
LOCs to insert local adverse events reporting procedure.
©2023 GSK group of companies or its licensor. GlaxoSmithKline Biologicals SA. Rixensart, Belgium.
NX-GBL-RSA-WCNT-220003 | January 2023